Remiges Ventures, Inc.
Seattle · Pre-Seed–Seed · 19 people tracked
Investment thesis
Remiges Ventures supports drug discovery and therapeutics research through its RDiscovery Fund, which incubates early-stage projects. The fund's portfolio includes companies working on regenerative therapies, secretome-based biologics, and other advanced therapeutic modalities addressing conditions such as Parkinson's-related dyskinesia, smell loss, and age-related muscle dysfunction.
Source: firm website, verified Jul 20, 2026.
Team · 19 people
from the firm's website
What they invest in
from 4 of 23 portfolio companiesBiotech ×4Medical Devices ×2AI & Machine Learning ×1Digital Health ×1Healthtech ×1
HQs:Germany×1Japan×1United States×1
Investments · 23 tracked
founders shown can be your intro pathDevelops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.
Cyrano Therapeutics develops pharmaceutical therapies for long-term loss of smell and taste, conditions affecting millions of people worldwide, particularly those experiencing post-viral olfactory dysfunction. The company is advancing CYR-064, a potential treatment for hyposmia that demonstrated safety and efficacy in Phase 2 clinical trials.
BiotechMedical Devices
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)
Kupando develops dual TLR4/7 agonist therapies, particularly KUP101, to treat solid tumors and infectious diseases including antimicrobial-resistant infections. The company's approach harnesses innate immune activation and trained immunity to address cancer and infectious disease indications.
AI & Machine LearningBiotechSchönefeld, DE
Johanna Holldack(CEO & Founder)
Restore Vis is a life sciences company founded by a vitreoretinal surgeon and clinician scientist focused on addressing inflammation, aging, neurodegeneration and angiogenesis through translational research from drug discovery to clinical trials. The company develops treatments for ophthalmology and vision-related conditions.
BiotechDigital HealthHealthtechMedical DevicesTokyo, JP
Dr. Rajendra S. Apte(Paul A. Cibis Distinguished Professor; Vice Chair of Innovation and Translation; Founder)
Board seats · per SEC filings
what is this? ⓘ$2M raise · filed Sep 2021 · via Kazuhiko Nonomura
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Remiges Ventures, Inc. invest at?
- Remiges Ventures, Inc. invests at the Pre-Seed, Seed stages.
- What sectors does Remiges Ventures, Inc. focus on?
- Remiges Ventures, Inc. focuses on Biotech, Deep Tech.
- Where is Remiges Ventures, Inc. located?
- Remiges Ventures, Inc. is headquartered in Seattle, US.
Similar investors
Boundary Capital invests in high-growth private technology companies focused on creating positive impact at scale. The firm's team brings combined expertise in life sciences, AI, and engineering, with a track record of founding, investing in, and exiting multiple ventures.
Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas across therapeutics, consumer applications, and deep technology sectors.
Data Collective identifies and supports ambitious company founders developing technology-driven solutions. The firm focuses on companies using innovation to restore predictability in an unstable world, with demonstrated expertise across clean energy, gene therapy, sustainable agriculture, and machine learning applications in healthcare.
Hyderabad Angels is one of India's leading angel networks, comprising experienced entrepreneurs, industrialists, and family offices. The network provides capital, mentorship, and networks to early-stage startups, leveraging the lived experience and relationships of its members across multiple industries and economic cycles.
Innovestor is a Nordic investment group active across early-stage platforms including Angel CoFund, Life Science Fund, and Growth Fund III. The firm completed 74 investments in 2025 (23 initial and 51 follow-on rounds) and achieved a €24 million real estate exit. Innovestor also operates Energy Storage and Corporate Venturing investment platforms.